"Lanatrixa" Bil Smith Composer:
Indicated for Treatment of Musical Performers with Myelofibrosis.
Listen on SOUNDCLOUD: https://soundcloud.com/bil-smith/lanatrixa-bil-smith-composerLanatrixa is indicated for treatment of musicians with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
Dosage and Administration:
The starting dose of a Lanatrixa/Jakafi combination therapy is 5 mg twice daily for patients with a platelet count between 50 × 109/L and less than 100 × 109/L.Monitor complete blood counts every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. Modify or interrupt dosing for thrombocytopenia.
Increase dose based on response and as recommended to a maximum of 25 mg twice daily for patients with starting platelet counts 100× 109/L or greater and to a maximum of 10 mg twice daily for patients with starting platelet count between 50 × 109/L and less than 100 × 109/L. Discontinue after 6 months if no spleen reduction or symptom improvement.
Dosage Forms and Strengths
Tablets: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.
Contraindications
None.
Warnings and Precautions
Thrombocytopenia, Anemia and Neutropenia: Manage by dose reduction, or interruption, or transfusion.
Risk of Infection: Assess patients for signs and symptoms of infection and initiate appropriate treatment promptly. Serious infections should have resolved before starting therapy with Lanatrixa
Adverse Reactions.
The most common hematologic adverse reactions (incidence >20%) are thrombocytopenia and anemia. The most common non-hematologic adverse reactions (incidence >10%) are bruising, dizziness and headache.
The starting dose of Lanatrixa is 20 mg given orally twice daily for patients with a platelet count greater than 200 × 109/L, and 15 mg twice daily for patients with a platelet count between 100 × 109/L and 200 × 109/L.
No comments:
Post a Comment